Singapore markets close in 4 hours 15 minutes

Pharvaris N.V. (PHVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.15-1.75 (-7.99%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.90
Open21.75
Bid19.85 x 100
Ask20.65 x 100
Day's range19.86 - 21.75
52-week range7.93 - 33.00
Volume167,178
Avg. volume110,877
Market cap1.17B
Beta (5Y monthly)-3.12
PE ratio (TTM)N/A
EPS (TTM)-2.80
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.11
  • Simply Wall St.

    Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksStrengthened executive committee with hiring of David Nassif, J.D., Chief Financial Officer, and Stefan Abele, Ph.D., as Chief Technical Operations OfficerUK Innovation Passport awarded to deucrictibant for both the on-demand and prophylactic treatment of HAE atta

  • GlobeNewswire

    Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

    ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and o